Consensus Nuvalent, Inc.

Equities

NUVL

US6707031075

Real-time Estimate Cboe BZX Other stock markets 01:13:09 2024-06-05 pm EDT			5-day change	1st Jan Change
72.5 ^USD	+3.16%		+9.68%	-1.58%

May. 17	Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing	MT
May. 16	Nuvalent Gets FDA Breakthrough Therapy Designation for Lung-Cancer Treatment	DJ

Evolution of the average Target Price on Nuvalent, Inc.

Price target over the last 5 years

History of analyst recommendation changes

32.wVbjNMk3KmKaXQBE_CYjGso3nKEK_oVtIRdKuRU86_I.ohWnRb1zcwbdK0UwzEBvWflB2Mlhn_YjSH0Qzmd4srSQZ6pbmnBTEe8xSQ~ef97800cc6e64eb260465e3e08e287ff

Analyst Recommendations on Nuvalent, Inc.

Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing	May. 17	MT
Nuvalent Insider Sold Shares Worth $2,605,525, According to a Recent SEC Filing	May. 08	MT
Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing	May. 01	MT
Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing	Apr. 17	MT
Jefferies Initiates Nuvalent With Buy Rating, $97 Price Target	Apr. 17	MT
Nuvalent Insider Sold Shares Worth $2,566,479, According to a Recent SEC Filing	Apr. 10	MT
Nuvalent Insider Sold Shares Worth $1,654,311, According to a Recent SEC Filing	Apr. 01	MT
Leerink Partners Upgrades Nuvalent to Outperform From Market Perform, Raises Price Target to $110 From $69	Apr. 01	MT
Nuvalent Insider Sold Shares Worth $1,550,229, According to a Recent SEC Filing	Mar. 25	MT
BMO Capital Raises Price Target on Nuvalent to $102 From $93, Maintains Outperform Rating	Feb. 28	MT
Baird Initiates Nuvalent With Outperform Rating, Price Target is $105	Feb. 23	MT
Wedbush Raises Nuvalent's Price Target to $99 From $82, Maintains Outperform Rating	Feb. 12	MT
Wedbush Raises Nuvalent's PT to $82 From $74 After Announced 3-Year Plan to Place At Least One Lead Asset on Market by 2026; Keeps Outperform Rating	Jan. 08	MT
BMO Capital Adjusts Nuvalent Price Target to $79 From $73, Maintains Outperform Rating	23-10-18	MT
Wedbush Raises Nuvalent Price Target to $74 From $65, Maintains Outperform Rating	23-10-13	MT
JPMorgan Adjusts Price Target on Nuvalent to $68 From $51, Maintains Overweight Rating	23-10-05	MT
BMO Capital Adjusts Price Target on Nuvalent to $73 From $52, Keeps Outperform Rating	23-10-05	MT
Wedbush Raises Nuvalent's PT to $65 From $53 After Positive Phase 1 Trial Data on NVL-655 in Advanced ALK-Positive Lung Cancer; Keeps Outperform Rating	23-10-05	MT
Nuvalent Shares Rise After Stifel Starts Coverage With Buy Rating	23-09-27	MT
Stifel Initiates Nuvalent With Buy Rating	23-09-27	MT
SVB Securities Initiates Nuvalent With Market Perform Rating, $42 Price Target	23-08-08	MT
Guggenheim Starts Nuvalent at Buy With $56 Price Target	23-07-24	MT
JPMorgan Chase Raises Price Target on Nuvalent to $48 From $37, Maintains Overweight Rating	23-06-23	MT
Wedbush Raises Nuvalent's Price Target to $53 From $40, Outperform Rating Kept	23-05-11	MT
Wedbush Lifts Nuvalent's Price Target to $40 From $39, Notes Progress Across Pipeline, 'Strong' Balance Sheet; Keeps Outperform Rating	23-03-16	MT